Knockdown of MVK does not lead to changes in NALP3 expression or activation

Fulvio Celsi, Elisa Piscianz, Maurizio Romano, Sergio Crovella

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Mutations in the Mevalonate Kinase gene (MVK) are causes of a rare autoinflammatory disease: Mevalonate Kinase Deficiency and its more acute manifestation, Mevalonic Aciduria. The latter is characterized, among other features, by neuroinflammation, developmental delay and ataxia, due to failed cerebellar development or neuronal death through chronic inflammation. Pathogenesis of neuroinflammation in Mevalonate Kinase Deficiency and Mevalonic Aciduria has not yet been completely clarified, however different research groups have been suggesting the inflammasome complex as the key factor in the disease development. A strategy to mimic this disease is blocking the mevalonate pathway, using HMG-CoA reductase inhibitors (Statins), while knock-out mice for Mevalonate Kinase are non-vital and their hemyzygous (i.e only one copy of gene preserved) littermate display almost no pathological features. Findings: We sought to generate a murine cellular model closely resembling the pathogenic conditions found in vivo, by direct silencing of Mevalonate Kinase gene. Knockdown of Mevalonate Kinase in a murine microglial cellular model (BV-2 cells) results in neither augmented NALP3 expression nor increase of apoptosis. On the contrary, statin treatment of BV-2 cells produces an increase both in Mevalonate Kinase and NALP3 expression. Conclusions: MKD deficiency could be due or affected by protein accumulation leading to NALP3 activation, opening novel questions about strategies to tackle this disease.

Original languageEnglish
Article number048
JournalJournal of Inflammation (United Kingdom)
Volume12
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

mevalonate kinase
Mevalonate Kinase Deficiency
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Genes
Chemical activation
Inflammasomes
Mevalonic Acid
Ataxia
Rare Diseases
Knockout Mice
Apoptosis
Inflammation
Mutation
Display devices

Keywords

  • Autoimmunity
  • Immunology
  • Inflammation
  • Mevalonate kinase deficiency

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry

Cite this

Knockdown of MVK does not lead to changes in NALP3 expression or activation. / Celsi, Fulvio; Piscianz, Elisa; Romano, Maurizio; Crovella, Sergio.

In: Journal of Inflammation (United Kingdom), Vol. 12, No. 1, 048, 2015.

Research output: Contribution to journalArticle

@article{147efd461a9040c68c3567349f7e61a6,
title = "Knockdown of MVK does not lead to changes in NALP3 expression or activation",
abstract = "Background: Mutations in the Mevalonate Kinase gene (MVK) are causes of a rare autoinflammatory disease: Mevalonate Kinase Deficiency and its more acute manifestation, Mevalonic Aciduria. The latter is characterized, among other features, by neuroinflammation, developmental delay and ataxia, due to failed cerebellar development or neuronal death through chronic inflammation. Pathogenesis of neuroinflammation in Mevalonate Kinase Deficiency and Mevalonic Aciduria has not yet been completely clarified, however different research groups have been suggesting the inflammasome complex as the key factor in the disease development. A strategy to mimic this disease is blocking the mevalonate pathway, using HMG-CoA reductase inhibitors (Statins), while knock-out mice for Mevalonate Kinase are non-vital and their hemyzygous (i.e only one copy of gene preserved) littermate display almost no pathological features. Findings: We sought to generate a murine cellular model closely resembling the pathogenic conditions found in vivo, by direct silencing of Mevalonate Kinase gene. Knockdown of Mevalonate Kinase in a murine microglial cellular model (BV-2 cells) results in neither augmented NALP3 expression nor increase of apoptosis. On the contrary, statin treatment of BV-2 cells produces an increase both in Mevalonate Kinase and NALP3 expression. Conclusions: MKD deficiency could be due or affected by protein accumulation leading to NALP3 activation, opening novel questions about strategies to tackle this disease.",
keywords = "Autoimmunity, Immunology, Inflammation, Mevalonate kinase deficiency",
author = "Fulvio Celsi and Elisa Piscianz and Maurizio Romano and Sergio Crovella",
year = "2015",
doi = "10.1186/s12950-015-0048-5",
language = "English",
volume = "12",
journal = "Journal of inflammation",
issn = "1078-7852",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Knockdown of MVK does not lead to changes in NALP3 expression or activation

AU - Celsi, Fulvio

AU - Piscianz, Elisa

AU - Romano, Maurizio

AU - Crovella, Sergio

PY - 2015

Y1 - 2015

N2 - Background: Mutations in the Mevalonate Kinase gene (MVK) are causes of a rare autoinflammatory disease: Mevalonate Kinase Deficiency and its more acute manifestation, Mevalonic Aciduria. The latter is characterized, among other features, by neuroinflammation, developmental delay and ataxia, due to failed cerebellar development or neuronal death through chronic inflammation. Pathogenesis of neuroinflammation in Mevalonate Kinase Deficiency and Mevalonic Aciduria has not yet been completely clarified, however different research groups have been suggesting the inflammasome complex as the key factor in the disease development. A strategy to mimic this disease is blocking the mevalonate pathway, using HMG-CoA reductase inhibitors (Statins), while knock-out mice for Mevalonate Kinase are non-vital and their hemyzygous (i.e only one copy of gene preserved) littermate display almost no pathological features. Findings: We sought to generate a murine cellular model closely resembling the pathogenic conditions found in vivo, by direct silencing of Mevalonate Kinase gene. Knockdown of Mevalonate Kinase in a murine microglial cellular model (BV-2 cells) results in neither augmented NALP3 expression nor increase of apoptosis. On the contrary, statin treatment of BV-2 cells produces an increase both in Mevalonate Kinase and NALP3 expression. Conclusions: MKD deficiency could be due or affected by protein accumulation leading to NALP3 activation, opening novel questions about strategies to tackle this disease.

AB - Background: Mutations in the Mevalonate Kinase gene (MVK) are causes of a rare autoinflammatory disease: Mevalonate Kinase Deficiency and its more acute manifestation, Mevalonic Aciduria. The latter is characterized, among other features, by neuroinflammation, developmental delay and ataxia, due to failed cerebellar development or neuronal death through chronic inflammation. Pathogenesis of neuroinflammation in Mevalonate Kinase Deficiency and Mevalonic Aciduria has not yet been completely clarified, however different research groups have been suggesting the inflammasome complex as the key factor in the disease development. A strategy to mimic this disease is blocking the mevalonate pathway, using HMG-CoA reductase inhibitors (Statins), while knock-out mice for Mevalonate Kinase are non-vital and their hemyzygous (i.e only one copy of gene preserved) littermate display almost no pathological features. Findings: We sought to generate a murine cellular model closely resembling the pathogenic conditions found in vivo, by direct silencing of Mevalonate Kinase gene. Knockdown of Mevalonate Kinase in a murine microglial cellular model (BV-2 cells) results in neither augmented NALP3 expression nor increase of apoptosis. On the contrary, statin treatment of BV-2 cells produces an increase both in Mevalonate Kinase and NALP3 expression. Conclusions: MKD deficiency could be due or affected by protein accumulation leading to NALP3 activation, opening novel questions about strategies to tackle this disease.

KW - Autoimmunity

KW - Immunology

KW - Inflammation

KW - Mevalonate kinase deficiency

UR - http://www.scopus.com/inward/record.url?scp=84924086103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924086103&partnerID=8YFLogxK

U2 - 10.1186/s12950-015-0048-5

DO - 10.1186/s12950-015-0048-5

M3 - Article

AN - SCOPUS:84924086103

VL - 12

JO - Journal of inflammation

JF - Journal of inflammation

SN - 1078-7852

IS - 1

M1 - 048

ER -